DE69833686D1 - Konstitutive expression von nicht-infektiöser hiv-ähnlicher teilchen - Google Patents

Konstitutive expression von nicht-infektiöser hiv-ähnlicher teilchen

Info

Publication number
DE69833686D1
DE69833686D1 DE69833686T DE69833686T DE69833686D1 DE 69833686 D1 DE69833686 D1 DE 69833686D1 DE 69833686 T DE69833686 T DE 69833686T DE 69833686 T DE69833686 T DE 69833686T DE 69833686 D1 DE69833686 D1 DE 69833686D1
Authority
DE
Germany
Prior art keywords
hiv
constitutive expression
particles
modified
genome
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
DE69833686T
Other languages
English (en)
Other versions
DE69833686T2 (de
Inventor
Benjamin Rovinski
Fei-Long Yao
Xian Cao
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Sanofi Pasteur Ltd
Original Assignee
Aventis Pasteur Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=25537545&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=DE69833686(D1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Aventis Pasteur Ltd filed Critical Aventis Pasteur Ltd
Application granted granted Critical
Publication of DE69833686D1 publication Critical patent/DE69833686D1/de
Publication of DE69833686T2 publication Critical patent/DE69833686T2/de
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/18—Antivirals for RNA viruses for HIV
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2740/00—Reverse transcribing RNA viruses
    • C12N2740/00011—Details
    • C12N2740/10011—Retroviridae
    • C12N2740/16011—Human Immunodeficiency Virus, HIV
    • C12N2740/16023—Virus like particles [VLP]
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2740/00—Reverse transcribing RNA viruses
    • C12N2740/00011—Details
    • C12N2740/10011—Retroviridae
    • C12N2740/16011—Human Immunodeficiency Virus, HIV
    • C12N2740/16111—Human Immunodeficiency Virus, HIV concerning HIV env
    • C12N2740/16122—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2740/00—Reverse transcribing RNA viruses
    • C12N2740/00011—Details
    • C12N2740/10011—Retroviridae
    • C12N2740/16011—Human Immunodeficiency Virus, HIV
    • C12N2740/16311—Human Immunodeficiency Virus, HIV concerning HIV regulatory proteins
    • C12N2740/16322—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Virology (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Molecular Biology (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Genetics & Genomics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Oncology (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Communicable Diseases (AREA)
  • Pharmacology & Pharmacy (AREA)
  • AIDS & HIV (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Saccharide Compounds (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
DE69833686T 1997-12-16 1998-12-14 Konstitutive expression von nicht-infektiöser hiv-ähnlicher teilchen Expired - Lifetime DE69833686T2 (de)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US08/991,773 US6121021A (en) 1997-12-16 1997-12-16 Constitutive expression of non-infectious HIV-like particles
US991773 1997-12-16
PCT/CA1998/001164 WO1999031250A2 (en) 1997-12-16 1998-12-14 Constitutive expression of non-infectious hiv-like particles

Publications (2)

Publication Number Publication Date
DE69833686D1 true DE69833686D1 (de) 2006-04-27
DE69833686T2 DE69833686T2 (de) 2006-11-30

Family

ID=25537545

Family Applications (1)

Application Number Title Priority Date Filing Date
DE69833686T Expired - Lifetime DE69833686T2 (de) 1997-12-16 1998-12-14 Konstitutive expression von nicht-infektiöser hiv-ähnlicher teilchen

Country Status (12)

Country Link
US (2) US6121021A (de)
EP (1) EP1038001B8 (de)
JP (1) JP2004509601A (de)
AT (1) ATE318909T1 (de)
AU (1) AU749174B2 (de)
BR (1) BR9813626A (de)
CA (1) CA2312943C (de)
DE (1) DE69833686T2 (de)
DK (1) DK1038001T3 (de)
ES (1) ES2262250T3 (de)
PT (1) PT1038001E (de)
WO (1) WO1999031250A2 (de)

Families Citing this family (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6080408A (en) * 1994-08-22 2000-06-27 Connaught Laboratories Limited Human immunodeficiency virus type 1 nucleic acids devoid of long terminal repeats capable of encoding for non-infectious, immunogenic, retrovirus-like particles
US7135191B2 (en) * 1997-09-04 2006-11-14 Zsolt Istvan Hertelendy Urogenital or anorectal transmucosal vaccine delivery system
US6121021A (en) * 1997-12-16 2000-09-19 Connaught Laboratories Limited Constitutive expression of non-infectious HIV-like particles
EP1083230A1 (de) * 1999-09-10 2001-03-14 Academisch Medisch Centrum Amsterdam Virale Replikons und von induzierenden Wirkstoffen abhängige Viren
US20040105871A1 (en) * 2000-03-02 2004-06-03 Robinson Harriet L. Compositions and methods for generating an immune response
US8623379B2 (en) * 2000-03-02 2014-01-07 Emory University Compositions and methods for generating an immune response
CN1311871C (zh) 2000-03-02 2007-04-25 爱莫里大学 Dna表达载体及其应用方法
EP1776961A1 (de) * 2000-04-27 2007-04-25 Sanofi Pasteur Limited Impfung gegen HIV
DK1280551T3 (da) * 2000-04-27 2007-05-21 Sanofi Pasteur Ltd Vacciner mod HIV-infektion
US7122180B2 (en) * 2000-10-23 2006-10-17 Children's Medical Center Corporation DNA vectors containing mutated HIV proviruses
PT1372710E (pt) * 2001-03-08 2009-12-21 Us Gov Health & Human Serv Vam modificado que expressa os genes gag e pol do envelope de vih
WO2004042001A2 (en) * 2002-05-17 2004-05-21 Emory University Virus-like particles, methods of preparation, and immonogenic compositions
US9045727B2 (en) * 2002-05-17 2015-06-02 Emory University Virus-like particles, methods of preparation, and immunogenic compositions
EP1677832A1 (de) * 2003-09-09 2006-07-12 VIRxSYS Corporation Auf lentivirus-vektor basierende wege zur erzeugung einer immunantwort gegen hiv beim menschen
US20090257983A1 (en) * 2008-04-11 2009-10-15 Scheiber Lane Bernard Medical treatment device for treating aids by utilizing modified human immunodeficiency virus virions to insert anti-viral medications into t-helper cells
US20110293694A1 (en) * 2010-05-31 2011-12-01 Scheiber Lane Bernard Quantum unit of inheritance vector therapy method
US20110293693A1 (en) * 2010-05-31 2011-12-01 Scheiber Lane Bernard Quantum unit of inheritance vector therapy
EP3173096A1 (de) 2011-04-06 2017-05-31 Biovaxim Limited Pharmazeutische verbindungen zur prävention und/oder behandlung einer hiv-erkrankung bei menschen

Family Cites Families (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5001230A (en) * 1988-02-18 1991-03-19 Schering Corporation T cell activation markers
GB8923123D0 (en) * 1989-10-13 1989-11-29 Connaught Lab A vaccine for human immunodeficiency virus
EP0496794A1 (de) * 1989-10-16 1992-08-05 Whitehead Institute For Biomedical Research Nichtinfektiöse partikeln von hiv-1 und verwendungen davon
EP0502105A4 (en) * 1989-11-20 1993-02-24 Oncogen Limited Partnership Non-replicating recombinant-made retroviral particles used as antiviral agents and immunogens
WO1991015238A1 (en) * 1990-04-03 1991-10-17 Genentech, Inc. Methods and compositions for vaccination against hiv
JPH08500005A (ja) * 1992-03-27 1996-01-09 ホワイトヘッド インスティチュート フォー バイオメディカル リサーチ 非感染性ｈｉｖ粒子およびその用途
NZ267838A (en) * 1993-06-07 1997-12-19 Genentech Inc Preparation of an hiv gp 120 subunit vaccine involving determining a neutralising epitope in the v2 and/or c4 domains
JPH08511007A (ja) * 1993-06-09 1996-11-19 コノート ラボラトリーズ リミテッド タンデム合成ｈｉｖ−１ペプチド
US6080408A (en) * 1994-08-22 2000-06-27 Connaught Laboratories Limited Human immunodeficiency virus type 1 nucleic acids devoid of long terminal repeats capable of encoding for non-infectious, immunogenic, retrovirus-like particles
EP0904392B1 (de) * 1996-10-17 2001-01-24 Oxford Biomedica (UK) Limited Retrovirale vektoren
IL132164A0 (en) * 1997-04-09 2001-03-19 Chang Lung Ji Animal model for evaluation of vaccines
US6121021A (en) * 1997-12-16 2000-09-19 Connaught Laboratories Limited Constitutive expression of non-infectious HIV-like particles

Also Published As

Publication number Publication date
DE69833686T2 (de) 2006-11-30
PT1038001E (pt) 2006-07-31
EP1038001A2 (de) 2000-09-27
DK1038001T3 (da) 2006-07-10
AU749174B2 (en) 2002-06-20
EP1038001B8 (de) 2006-09-13
AU1657799A (en) 1999-07-05
CA2312943C (en) 2009-02-24
US6121021A (en) 2000-09-19
CA2312943A1 (en) 1999-06-24
ES2262250T3 (es) 2006-11-16
BR9813626A (pt) 2002-07-23
WO1999031250A2 (en) 1999-06-24
ATE318909T1 (de) 2006-03-15
EP1038001B1 (de) 2006-03-01
JP2004509601A (ja) 2004-04-02
US6572863B1 (en) 2003-06-03
WO1999031250A3 (en) 1999-08-19

Similar Documents

Publication Publication Date Title
ATE318909T1 (de) Konstitutive expression von nicht-infektiöser hiv-ähnlicher teilchen
PL332876A1 (en) Lentoviral vectors
ATE349540T1 (de) Expression der bazillus thuringiensis cry- proteine in pflanzen-plastiden
AU2002257420A1 (en) A system for inducible expression in eukaryotic cells
NO983102D0 (no) Uttrykk og forsterkning av sekvenselementer (EASE) for eukaryote ekspresjonssystemer
DK0452484T3 (da) Fremstilling af proteiner ved homolog rekombination
CA2305013A1 (en) Fusion proteins comprising hiv-1 tat and/or nef proteins
DE69637147D1 (de) Transportproteine und deren verwendungen
ATE380822T1 (de) Funf-helix protein
TR199801933A2 (xx) Biyolojik olarak tolare edilebilen d���k molek�ler polietileniminler.
EP1006196A3 (de) Retrovirale, mit LCMV-Glykoprotein pseudotypisierte Hybrid-Vektoren
DK1702979T3 (da) Improved keratinocyte culture and uses thereof
AU5539898A (en) Nucleic acid construct for the cell cycle regulated expression of structural genes
IE840258L (en) Expression of gene products.
CY1107431T1 (el) Σωματιδια για γoνιδιακη θεραπεια
TR200001046T2 (tr) Homolog rekombinasyonda pozitif-negatif seçimi.
DK0843731T3 (da) Adenovirusvektorer til genterapi
AU2520595A (en) Virosome-mediated intracellular delivery of therapeutic agents
DK203588A (da) Fremgangsmaade til fremstilling af proteiner
EA199900144A1 (ru) Способ индуцирования вирусной устойчивости в растении
DE3577994D1 (de) Vergroessernde virale dna-segmente.
EP0336383A3 (de) Menschliches rekombinantes Lymphotoxin
DK176387D0 (da) Fremgangsmaade til frembringelse af et funktionelt polypeptid i en eukaryot vaertscelle ved anvendelse af en rekombinant dna udtrykkelsesvektor omfattende en bk virusforstaerker
PT1032418E (pt) Replicoes compactos do virus epstein-barr
NO912099D0 (no) Ekspresjon av hiv-proteiner i drosophilia-celler.

Legal Events

Date Code Title Description
8327 Change in the person/name/address of the patent owner

Owner name: SANOFI PASTEUR LTD., TORONTO, ONTARIO, CA

8363 Opposition against the patent